Is Diffuse Large B Cell Lymphoma Non Hodgkins?

Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma. It is the most common form of this blood cancer. Knowing the difference between Hodgkin and non-Hodgkin lymphoma matters because the two diseases behave differently and require different treatments.

What Is Diffuse Large B Cell Lymphoma?

Diffuse large B cell lymphoma is a cancer that starts in white blood cells called B lymphocytes. These cells normally help your body fight infection. When they become cancerous, they grow out of control and form tumors in lymph nodes or other organs.

The “diffuse” part of the name means the cancer cells spread throughout the lymph node rather than growing in clusters. The “large” part describes the size of the abnormal cells under a microscope. The “B cell” part tells you which type of immune cell became cancerous.

DLBCL is an aggressive lymphoma. That sounds frightening, but aggressive in this context means the cancer grows quickly. This is important because fast-growing cancers often respond well to chemotherapy. The goal is to catch it early and treat it aggressively.

How Is DLBCL Different From Hodgkin Lymphoma?

Hodgkin lymphoma and non-Hodgkin lymphoma are two different diseases. They both affect the lymphatic system, but they have distinct features.

The main difference is the presence of a specific abnormal cell called the Reed-Sternberg cell. This cell is only found in Hodgkin lymphoma. If you do not have Reed-Sternberg cells, the diagnosis is non-Hodgkin lymphoma.

DLBCL falls firmly into the non-Hodgkin category. It accounts for about one in three cases of non-Hodgkin lymphoma worldwide. It is the most common aggressive lymphoma in adults.

Treatment approaches differ between the two types. Hodgkin lymphoma and non-Hodgkin lymphoma use different chemotherapy regimens. That is why an accurate diagnosis matters so much before starting treatment.

What Causes Diffuse Large B Cell Lymphoma?

The exact cause of DLBCL is not fully understood. Most people who develop it have no known risk factors.

Some factors are associated with a higher risk. Age is one. DLBCL is most often diagnosed in people in their 60s and 70s, though it can occur at any age. People with weakened immune systems face higher risk. This includes people with HIV, organ transplant recipients taking immunosuppressive drugs, and people with autoimmune conditions.

Some infections are linked to DLBCL development. Epstein-Barr virus is associated with some cases, particularly in older adults and people with weakened immunity. Hepatitis C infection has also been linked to certain lymphomas.

Most people with these risk factors never develop lymphoma. Having a risk factor does not mean you will get the disease.

What Are the Symptoms of DLBCL?

The most common symptom is painless swelling in the lymph nodes. You might notice a lump in your neck, armpit, or groin. These lumps can grow quickly over weeks.

Some people develop B symptoms. These are a specific set of symptoms that include:

• Fever that comes and goes without an infection
• Night sweats so heavy they soak through clothing
• Unexplained weight loss of more than 10 percent of body weight over six months

Because DLBCL can start outside the lymph nodes, other symptoms depend on where the cancer grows. It can appear in the gastrointestinal tract, causing abdominal pain or bleeding. It can grow in the bones, causing pain. It can even start in the brain or spinal cord, causing neurological symptoms.

These symptoms overlap with many other conditions. Most people with these symptoms do not have lymphoma. But if you have persistent swelling or unexplained B symptoms, see a doctor.

How Is DLBCL Diagnosed?

Diagnosis requires a biopsy. This means removing a piece of the affected tissue so a pathologist can examine it under a microscope.

The preferred biopsy is an excisional biopsy. This removes an entire lymph node. A needle biopsy that takes only a small sample may not provide enough tissue for all the tests needed.

The pathologist looks for large B cells that are spreading diffusely through the node. They also run tests to identify specific proteins on the surface of the cancer cells. These tests help classify the lymphoma more precisely.

Once the diagnosis is confirmed, you will need staging tests. This usually includes imaging scans such as PET or CT scans. These scans show where the lymphoma is located in your body. Staging tells your doctor how widespread the disease is, which guides treatment decisions.

Blood tests and sometimes a bone marrow biopsy are also part of the workup. The bone marrow biopsy checks whether lymphoma cells have reached the marrow.

What Are the Treatment Options for DLBCL?

Treatment for DLBCL typically begins soon after diagnosis because the cancer grows quickly. The standard first treatment is a combination of chemotherapy and an immunotherapy drug.

The most common regimen is called R-CHOP. The “R” stands for rituximab, a targeted antibody that attaches to B cells. CHOP refers to three chemotherapy drugs plus a steroid. This combination has been the standard of care for over two decades.

Most people receive six cycles of R-CHOP, with each cycle lasting about three weeks. The exact number of cycles depends on the stage of the disease and how well you respond to treatment.

Radiation therapy may be added in certain situations. This is most common for people who had a single area of disease and achieved a good response to chemotherapy.

For people whose lymphoma returns or does not respond to first treatment, options include different chemotherapy regimens, stem cell transplantation, or newer targeted therapies. Clinical trials may also be available.

Recent years have brought new options. Some people with certain genetic subtypes of DLBCL may benefit from adding other targeted drugs to their treatment. Your oncologist can explain whether these apply to your specific situation.

What Is the Prognosis for DLBCL?

Prognosis depends on several factors. The stage of the disease matters. Whether the lymphoma has spread to organs outside the lymph system matters. Your age and overall health matter too.

About 60 to 70 percent of people with DLBCL are cured with initial treatment. Cure means the cancer goes away and does not come back. This is one of the more treatable aggressive lymphomas.

Doctors use a scoring system to estimate prognosis. It considers age, stage, blood test results, and how many organs are involved. This score helps guide treatment intensity but does not predict any individual outcome with certainty.

People who achieve a complete remission after initial treatment have the best outlook. The risk of relapse is highest in the first two years after treatment. After five years without relapse, the chance of the lymphoma returning drops significantly.

What Is the Difference Between B Cell and T Cell Lymphoma?

Lymphoma is classified by which immune cell became cancerous. B cell lymphomas start in B lymphocytes. T cell lymphomas start in T lymphocytes. These are different types of white blood cells with different jobs.

B cells produce antibodies. T cells directly attack infected or abnormal cells. DLBCL is a B cell lymphoma, which is the most common type of non-Hodgkin lymphoma.

T cell lymphomas are much rarer and often harder to treat. They require different treatment approaches. This is why the biopsy must identify the exact cell type.

Can DLBCL Be Prevented?

There is no known way to prevent DLBCL. Most people who develop it have no identifiable risk factors.

You can reduce some general cancer risks by not smoking, limiting alcohol, staying physically active, and maintaining a healthy weight. But these habits have not been proven to prevent lymphoma specifically.

If you have chronic hepatitis C infection, treating it may reduce your lymphoma risk. Some research suggests this association, though the evidence is not definitive.

The most practical step is awareness. Knowing the symptoms and seeking medical attention promptly if they appear allows for earlier diagnosis. Earlier diagnosis generally leads to better outcomes.